重组人脑利钠肽在急性失代偿性心力衰竭中的应用研究

被引：3

作者：

容文明

吴杰贤

朱景成

机构：

[1] 台山市人民医院内科

来源：

国际医药卫生导报 | 2011年 / 12期

关键词：

重组人脑利钠肽; 急性失代偿性心力衰竭; 疗效;

D O I：

暂无

中图分类号：

R541.6 [血液循环衰竭];

学科分类号：

100201 [内科学];

摘要：

目的探讨重组人脑利钠肽（rhBNP）治疗急性失代偿性心力衰竭患者的临床疗效及安全性。方法将60例急性失代偿性心力衰竭患者随机分为对照组（n=30）和rhBNP组（n=30）,对照组接受常规治疗,rhBNP组在常规治疗的基础上加用冻干rhBNP（新活素）1.5μg/kg静脉冲击,0.0075μg/（kg·min）持续静注24 h。分别记录两组患者给药前及用药24 h后血流动力学、尿量、心功能改善情况,血肌酐及血N-末端脑钠肽前体（NT-proBNP）的变化。结果两组基线特征差异无显著性（P>0.05）;rhBNP组总有效率为96.7%,明显高于对照组的73.3%,差异有显著性（P<0.05）。hBNP组治疗后的心率、血压、中心静脉压、血NT-proBNP分别是（99±6）bpm、（121±8）/（80±4）mmHg、（8.15±1.89）cmH2O、（3426.95±590.02）pg/ml,较治疗前的（135±10）bpm、（169±18）/（105±11）mmHg、（15.07±3.71）cmH2O、（5989.44±983.48）pg/mL显著下降,差异有显著性（P<0.05）。rhBNP组治疗后的24 h尿量、LVEF分别是（1.8±0.4）L、（58±8）%,较治疗前的（1.0±0.2）L、（29±6）%明显升高,差异有显著性（P<0.05）。未见肾功能恶化。结论重组人脑利钠肽是改善急性失代偿性心力衰竭安全有效的药物。

引用

共 9 条

[1]

BNP和NT-pro-BNP检测阈值浓度选择的影响因素 [J].

梁晓莺 .

中国实用医药, 2007, (36) :161-163

[2]

Nesiritide in acute decompensated heart failure:current status and future perspectives..Mohammed SF;Korinek J;Chen HH;et al;.Rev Cardiovasc Med.2008, 03

[3]

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) [J].

Hernandez, Adrian F. ;

O'Connor, Christopher M. ;

Starling, Randall C. ;

Reist, Craig J. ;

Armstrong, Paul W. ;

Dickstein, Kenneth ;

Lorenz, Todd J. ;

Gibler, W. Brian ;

Hasselblad, Vic ;

Komajda, Michel ;

Massie, Barry ;

McMurray, John J. V. ;

Nieminen, Markku ;

Rouleau, Jean L. ;

Swedberg, Karl ;

Califf, Robert M. .

AMERICAN HEART JOURNAL, 2009, 157 (02) :271-277

[4]

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure [J].

Tang, W. H. Wilson ;

Francis, Gary S. ;

Morrow, David A. ;

Newby, L. Kristin ;

Cannon, Christopher P. ;

Jesse, Robert L. ;

Storrow, Alan B. ;

Christenson, Robert H. ;

Apple, Fred S. ;

Cannon, Christopher P. ;

Francis, Gary S. ;

Jesse, Robert L. ;

Morrow, David A. ;

Newby, L. Kristin ;

Ravkilde, Jan ;

Storrow, Alan B. ;

Tang, W. H. Wilson ;

Wu, Alan H. B. .

CIRCULATION, 2007, 116 (05) :E99-E109

[5]

Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction.[J].Ronald M. Witteles;David Kao;Dianne Christopherson;Kelly Matsuda;Randall H. Vagelos;Donald Schreiber;Michael B. Fowler.Journal of the American College of Cardiology.2007, 19

[6]

Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management [J].

Arnold, JMO ;

Liu, P ;

Demers, C ;

Dorian, P ;

Giannetti, N ;

Haddad, H ;

Heckman, GA ;

Howlett, JG ;

Ignaszewski, A ;

Johnstone, DE ;

Jong, P ;

McKelvie, RS ;

Moe, GW ;

Parker, JD ;

Rao, V ;

Ross, HJ ;

Sequeira, EJ ;

Svendsen, AM ;

Teo, K ;

Tsuyuki, RT ;

White, M .

CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (01) :23-45

[7]

N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients.[J]..Circulation.2004, 15

[8]

Safety and feasibility of using serial infusions of Nesiritide for heart failure in an outpatient setting (from the FUSIONI trial) [J].

Yancy, CW ;

Saltzberg, MT ;

Berkowitz, RL ;

Bertolet, B ;

Vijayaraghavan, K ;

Burnham, K ;

Oren, RM ;

Walker, K ;

Horton, DP ;

Silver, MA .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (05) :595-601

[9]

Comparison of the effects of Dobutamine and nesiritide (B-type natriuretic peptide) on ventricular ectopy in acutely decompensated ischemic versus nonischemic cardiomyopathy [J].

Burger, AJ ;

Aronson, D ;

Horton, DP ;

Burger, MR .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (11) :1370-1372

← 1 →